Prognostic factors in stage I/II non-small cell lung cancer

Lung Cancer

Volumn 33, Issue SUPPL. 1, 2001, Pages

  Junker, Klaus ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Angiogenesis; Apoptosis; Individual tumor cell dissemination; Oncogenes; Prognostic factors; Stage I II NSCLC; Tumor cell proliferation; Tumor suppressor genes

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; GROWTH FACTOR; VASCULOTROPIN;

ANGIOGENESIS; APOPTOSIS; ARTICLE; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CELL DIFFERENTIATION; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; MICROVASCULATURE; ONCOGENE; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; SURVIVAL TIME; TUMOR SUPPRESSOR GENE;

CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0034835427     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(01)00298-7     Document Type: Article

References (53)

1. Revisions in the international system for staging lung cancer
2. Prognostic factors in lung cancer: tables and comments
3. Bedeutung der regionalen lymphatischen Tumorzelldisseminierung bei Patienten mit resektablem nicht-kleinzelligem Bronchialcarcinom
4. Frequency and prognostic significance of isolated tumour cells in bone marrow of patients with non-small-cell lung cancer without overt metastases
5. Immunohistochemical assessment of individual tumor cells in lymph nodes of patients with non-small-cell lung cancer
6. A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, oncoprotein expression
7. Prognostic significance of the proliferation index in surgically resected non-small cell lung cancer
8. Ki-67 immunostaining and other prognostic factors including tobacco smoking in patients with resected nonsmall cell lung carcinoma
9. Prognostic value of MIB-1 in neuroendocrine tumours of the lung
10. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics
11. Apoptosis (The 1992 Frank Rose Memorial Lecture)
12. Enhanced apoptosis predicts shortened survival in non-small cell lung carcinoma
13. Prognostic significance of apoptotic index in completely resected non-small-cell lung cancer
14. Microvessel count predicts metastatic disease and survival in non-small cell lung cancer
15. Tumor angiogenesis and biologic markers in resected stage I NSCLC
16. Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma
17. Expression of vascular endothelial growth factor (VEGF) and its two receptors (VEGF-R1-Flt1 and VEGF-R2-Flk1/KDR) in non-small cell lung carcinomas (NSCLCs): correlation with angiogenesis and survival
18. Immunohistochemical detection of basic fibroblast growth factor as a prognostic indicator in pulmonary adenocarcinoma
19. Expression of p53 in premalignant and malignant squamous epithelium
20. Increased expression of mutant forms of p53 oncogene in primary lung cancer
21. The p53 gene is very frequently mutated in small cell lung cancer with a destinct nucleotide substitution pattern
22. Relationship of p53 overexpression and up-regulation of proliferating cell nuclear antigen with the clinical course of non-small cell lung cancer
23. Prognostic significance of p53 and ras gene abnormalities in lung adenocarcinoma patients with stage I disease after curative resection
24. Mutations of p53 gene as a predictor of poor prognosis in patients with non-small cell lung cancer
25. Accumulation of p53 protein correlates with poor prognosis in human lung cancer
26. Immunohistochemical study of p53 in human lung carcinomas
27. The relationship of p53 immunostaining to survival in carcinoma of the lung
28. Prognostic significance of p53 protein expression and DNA ploidy in surgically treated non-small-cell lung carcinomas
29. p53 immunostaining positivity is associated with reduced survival and is imperfectly correlated with gene mutation in resected non-small cell lung cancer
30. Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer
31. p53 gene mutations in non-small cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features
32. p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas
33. Symposium: apoptosis/programmed cell death the bcl-2 oncogene: apoptosis and neoplasia
34. Tumour suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo
35. Apoptosis regulation by interaction of Bcl- 2 protein and Raf-1 kinase
36. Expression of apoptosis-regulatory genes in lung tumour cell lines: relationship to p53 expression and relevance to acquired drug resistance
37. Bcl-2 protein and prognosis in patients with potentially curable non-small-cell lung cancer
38. Kip1 in non-small cell lung carcinoma: a prognostic factor independent of ras
39. K-ras oncogene activation in adenocarcinoma of the lung: frequency and possible clinical significance
40. Mutational activation of the K-ras oncogene: a possible pathogenetic factor in adenocarcinoma of the lung
41. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung
42. Prognostic significance of the expression of ras oncogene product in non-small cell lung cancer
43. Correlation between K-ras gene mutation and prognosis of patients with non-small cell lung carcinoma
44. neu expression in human lung adenocarcinomas predicts shortened survival
45. C-erb B-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas
46. Prognostic value of c-erbB-2 protein expression in human lung adenocarcinoma and squamous cell carcinoma
47. Sialomucin expression is associated with erbB-2 oncoprotein expression, early recurrence, and cancer death in non-small cell lung cancer
48. Use of possible synergistic expression of p53 and p185 as a prognostic tool for stage I non-small-cell lung cancer
49. Angiogenesis and molecular biologic substaging in patients with stage I non-small cell lung cancer
50. Telomerase activity as a prognostic indicator in stage I non-small cell lung cancer
51. Altered retinoblastoma protein expression in non-small cell lung cancer: its synergistic effects with alrered ras and p53 protein status on prognosis
52. Altered retinoblastoma protein expression and prognosis in early-stage non-small cell lung carcinoma